Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2009

01-03-2009 | Short Communication

Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report

Authors: Celalettin Camci, Alper Sevinc, Yilmaz Aslan, Mehmet Emin Kalender, Suleyman Buyukberber

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Login to get access

Abstract

Background

Ovarian cancer remains one of the most lethal of all gynecologic malignancies, accounting for more deaths than cervical and uterine cancer combined. Advanced ovarian cancer is a chemosensitive tumor and most patients initially respond to platinum-based combination chemotherapy with response rates of about 70%, including a high proportion of complete responses. However, despite aggressive surgery and chemotherapy, more than 80% of patients will relapse and will then be treated with second line chemotherapy with objective responses in about 20% of patients and even lower percentages of complete responses.

Case

We observed a 42-months of complete response with administration of 1-[2-tetrahydrofuryl]-5-fluorouracil mixed with uracil (UFT) in patient with platinium refractory ovarian cancer.

Conclusion

We report a complete remission of platinium refractory epitelial ovarian cancer with UFT monotherapy that was not reported previously.
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66PubMedCrossRef
2.
Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP (1983) Staging laparotomy in early ovarian cancer. JAMA 250:3072–3076PubMedCrossRef
3.
Samaritani R, Corrado G, Vizza E, Sbiroli C (2007) Cyclophosphamide “metronomic”chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer, doi:10.​1186/​1471-2407-7-65
4.
Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 19:1266–1274PubMed
5.
Latorre A, De Lena M, Catino A, Crucitta E, Sambiasi D, Guida M, Misino A, Lorusso V (2002) Epithelial ovarian cancer: second andthird line chemotherapy. Int J Oncol 21:179–186PubMed
6.
Sulkes A, Benner SE, Canetta RM (1998) Uracil-ftorafur: an oral fluoropyrimidine active in colorectal cancer. J Clin Oncol 16:3461–3475PubMed
7.
Hoff PM, Lassere Y, Pazdur R (1999) Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil (Review; 43 refs). Drugs 58:77–83PubMedCrossRef
8.
Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021–1027PubMed
9.
Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120–3125PubMedCrossRef
10.
Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK, Bristow RE (2005) Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 23:9338–9343PubMedCrossRef
11.
Liu PY, Alberts DS, Monk BJ, Brady M, Moon J, Markman M (2007) An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 25:3615–3620PubMedCrossRef
12.
Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB (2000) Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 92:1534PubMedCrossRef
13.
Sevinc A, Adli M, Kalender ME, Camci C (2007) Benign causes of increased serum CA-125 concentration. Lancet Oncol 8:1054–1055PubMedCrossRef
14.
Turk HM, Pekdemir H, Buyukberber S, Sevinc A, Camci C, Kocabas R, Tarakcioglu M, Buyukberber NM (2003) Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumour Biol 24:172–175PubMedCrossRef
15.
Sevinc A, Camci C, Turk HM, Buyukberber S (2003) How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology 65:1–6PubMedCrossRef
16.
Sevinc A, Sari R, Buyukberber S (2001) Cancer antigen 125: tumor or serosal marker in case of ascites? Arch Intern Med 161:2507–2508PubMedCrossRef
17.
Sevinc A, Buyukberber S, Sari R, Turk HM, Ates M (2000) Elevated serum CA-125 levels in patients with nephrotic syndrome-induced ascites. Anticancer Res 20:1201–1203PubMed
18.
Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M (2000) Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. Gynecol Oncol 77:254–257PubMedCrossRef
19.
Sevinc A, Buyukberber S, Sari R (2000) Elevated serum CA-125 levels: hepatitis or ascites? Gynecol Oncol 76:141–142PubMedCrossRef
20.
Look KY, Muss HB, Blessing JA, Morris M (1995) A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study. Am J Clin Oncol 18:19–22PubMedCrossRef
21.
Ohwada N, Nagayama M, Kosuge T, Tsukagoshi T, Ibuki Y, Igarashi M, Yazaki K, Ito T, Nogami Y, Kimura H (1992) Maintenance chemotherapy using UFT and FT for gynecological malignant tumors (in Japanese). The Gunma Prefectural Society for Study of Chemotherapy for Gynecological Cancer. Gan To Kagaku Ryoho 19:2219–2226PubMed
22.
Chen JT, Nakayama K, Shimizu Y, Yokosuka K, Teshima H, Hirai Y, Hamada T, Fujimoto I, Yamauchi K, Hasumi K (1990) Evaluation of UFT administration in patients with ovarian cancer who had no evidence of disease after the initial therapy (in Japanese). Gan To Kagaku Ryoho 17:407–412PubMed
23.
Tanaka K, Kodama S, Nakamura M, Takahashi T, Honma S, Maruhashi T, Tokunaga A, Takeuchi Y, Sudou N, Adachi S (1994) Clinical results of UFT against ovarian carcinoma (in Japanese). Gan To Kagaku Ryoho 2:1229–1233
Metadata
Title
Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report
Authors
Celalettin Camci
Alper Sevinc
Yilmaz Aslan
Mehmet Emin Kalender
Suleyman Buyukberber
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0775-x

Other articles of this Issue 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Go to the issue

Original Article

CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells

Original Article

Phase 0 clinical trials in oncology: a paradigm shift for early drug development?

Original Article

Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition

Original Article

ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair

Clinical Trial Report

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy

Original Article

Renal dysfunction during and after high-dose methotrexate

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits